Efficacy and safety of denosumab therapy for low bone mineral density in childhood cancer survivors: A report of preliminary experience

Huang, Ting‐Huan; Liu, Hsi‐Che; Hou, Jen‐Yin; Chang, Ching‐Yi; Sun, Fang‐Ju; Yeh, Ting‐Chi

doi:10.1002/pbc.27927

Cited by 11 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypokalemia and hypophosphatemia observed in current work is also referred in other studies related to leukemia 29,30 . Although hypocalcemia and hypochloremia observed in our study are also shown by other studies on childhood leukemia 31,32 . Furthermore, work presented here showed elevated CRP level, which was also observed in other recent studies 33–35 …”

Section: Resultssupporting

confidence: 92%

Biochemical and Hematologic Profiles in B-Cell Acute Lymphoblastic Leukemia Children

Khalid

Ahmed

Hasnain

2023

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

B-cell acute lymphoblastic leukemia is the most common type of leukemia found in children. Timely diagnosis, white blood cell count, age of onset, and sex are considered the most important prognostic factors in childhood leukemia. Hematological and biochemical profiles are crucially important to infer the health of leukemia patient pre-chemotherapy and post-chemotherapy treatment. In the current study 200 cases were taken and evaluated for hematological (complete blood count and white blood differential count) and biochemical parameters (renal function tests, liver function tests, serum electrolytes and serum proteins) by comparison with normal reference values. Most of the cases were male under 5 years of age. Hematology parameters including red blood cells, hemoglobin and platelet levels were relatively low whereas white blood cells level was high in cases as compared with normal reference value. Sex-wise and age-wise comparison of biochemical profile showed significant difference among B-cell acute lymphoblastic leukemia cases whereas hematological profile did not show any visible difference.

show abstract

Section: Resultssupporting

confidence: 92%

Biochemical and Hematologic Profiles in B-Cell Acute Lymphoblastic Leukemia Children

Khalid

Ahmed

Hasnain

2023

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

“…This finding is also emphasized by our control cohort's mean age and sex distribution: Mean age was significantly greater in controls compared with the patient cohort, and the percentage of females in controls was [33][34][35]. Moreover, the monoclonal anti-receptor activator of nuclear factor κ B (RANK)-ligand antibody denosumab has shown promising results by reducing fracture risk and increasing BMD [36,37]. However, these results were observed in postmenopausal females undergoing breast cancer treatment and childhood cancer survivors.…”

Section: Discussionmentioning

confidence: 63%

Identification of non-Hodgkin lymphoma patients at risk for treatment-related vertebral density loss and fractures

et al. 2020

View full text Add to dashboard Cite

Information on bone loss in treated non-Hodgkin's lymphoma patients is limited. In this study, we used CT to analyze bone loss as well as prevalent and incident fractures. We found severe bone loss, a high rate of fractures, and a novel association between bone loss and the international prognostic index. Introduction To investigate bone loss and fracture risk in non-Hodgkin-lymphoma (NHL) patients by (i) comparing treatmentrelated vertebral density (VD) loss in NHL patients with control subjects and (ii) investigating associations of VD loss versus fracture risk. Further, associations of VD loss and clinical parameters were investigated. Methods VD of 123 NHL patients was measured pre-and post-treatment in the L1, L2, and L3 vertebrae in routine computed tomography (CT) scans, performed between Jan 2016 and Mar 2017. Control measurements (n = 52) were obtained from CT colonographies between Sept 2003 and Sept 2017 and their subsequent follow-up-exams (10-137 months). Prevalent and incident (between baseline and follow-up) fractures were assessed in all subjects, and VD loss per year was calculated. Linear regression models were used to (i) compare VD loss between patients and controls and (ii) identify associations between VD loss and clinical parameters. Using logistic regression models, ORs for fractures per SD change in VD were assessed in patients. Analyses were adjusted for age, sex, and contrast application. Results NHL patients experienced significantly greater VD L1-3 loss than controls (P = 0.003), and greater VD L1-3 loss was associated with a greater likelihood of incident fractures (OR, [95%-CI], P 1.90, [1.03, 3.51], 0.04). Patients with an initial international prognostic index (IPI) of 5 suffered significantly greater VD loss compared with an IPI of 0 (P = 0.01). Conclusion Using VD measurements in routine CT scans, substantial vertebral bone loss in NHL patients could be documented with a high incidence of fractures.

show abstract

“…Huang et al. reported that denosumab is an available treatment for BMD reduction in pediatric cancer survivors [ 18 ]. We have also proven the efficacy and safety of denosumab in children and young adults with refractory osteoporosis [ 9 – 12 ], although there have been no reports on denosumab for Williams syndrome and osteoporosis.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of denosumab therapy for a 12-year-old female patient with Williams syndrome with osteoporosis and history of fractures: a case report

et al. 2021

View full text Add to dashboard Cite

Background A decrease in bone mineral density is common in patients with Williams syndrome. However, appropriate management for osteoporosis in Williams syndrome patients has not been established. We report the case of a 12-year-old female patient with Williams syndrome, who underwent denosumab treatment for osteoporosis. Case presentation A 12-year-old Japanese female patient with Williams syndrome was shown to have very low bone mineral density. Bone mineral density was evaluated before treatment and at 5, 9, 17, 23, and 29 months of treatment by dual-energy X-ray absorptiometry. After denosumab therapy for 29 months, lumbar and total hip bone mineral density values had increased by 51.6% and 37.6%, respectively. No new fractures occurred during the observation period. Conclusions To the best of our knowledge, this is the first experience with denosumab treatment in Williams syndrome patients with osteoporosis. Based on our findings, denosumab may be an effective treatment option for Williams syndrome patients with osteoporosis.

show abstract

Efficacy and safety of denosumab therapy for low bone mineral density in childhood cancer survivors: A report of preliminary experience

Cited by 11 publications

References 36 publications

Biochemical and Hematologic Profiles in B-Cell Acute Lymphoblastic Leukemia Children

Biochemical and Hematologic Profiles in B-Cell Acute Lymphoblastic Leukemia Children

Identification of non-Hodgkin lymphoma patients at risk for treatment-related vertebral density loss and fractures

Efficacy of denosumab therapy for a 12-year-old female patient with Williams syndrome with osteoporosis and history of fractures: a case report

Contact Info

Product

Resources

About